Myelodysplastic Syndromes
April 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Myelodysplastic Syndromes: Updates and Nuances.
Authors:Dao KT
Institution:Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Mail Code: UHN73C, 3181 South West Sam Jackson Park Road, Portland, OR 97239, USA. Electronic address: daok@ohsu.edu.
Journal:Med Clin North Am. 2017 Mar;101(2):333-350. doi: 10.1016/j.mcna.2016.09.006.

2:Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
Authors:Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL
Institution:From the Department of Medical Oncology, Division of Hematological Malignancies (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.). (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.).
Journal:N Engl J Med. 2017 Feb 9;376(6):536-547. doi: 10.1056/NEJMoa1611604.

3:Spectrum of complex chromosomal aberrations in a myelodysplastic syndrome and a brief review.
Authors:Ganguly BB, Dolai TK, De R, Kadam NN
Institution:MGM Center for Genetic Research and Diagnosis, MGM New Bombay Hospital, Navi Mumbai, Maharashtra, India.
Journal:J Cancer Res Ther. 2016 Jul-Sep;12(3):1203-1206. doi: 10.4103/0973-1482.197563.

4:Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis.
Authors:Takahashi S, Tsumanuma R, Aizawa K, Osakabe M, Maeda K, Omoto E
Institution:Department of Hematology, Hokkaido University Graduate School of Medicine, Japan.
Journal:Intern Med. 2016;55(22):3351-3356. Epub 2016 Nov 15.

5:Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.
Authors:Cremers EM, van Biezen A, de Wreede LC, Scholten M, Vitek A, Finke J, Platzbecker U, Beelen D, Schwerdtfeger R, Volin L, Harhalakis N, Blijlevens N, Nagler A, Kroger N, de Witte T
Institution:VU University Medical Center, Amsterdam, The Netherlands. e.cremers@vumc.nl. De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. e.cremers@vumc.nl.
Journal:Ann Hematol. 2016 Dec;95(12):1971-1978. Epub 2016 Sep 20.

6:Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Authors:Waszczuk-Gajda A, Madry K, Machowicz R, Drozd-Sokolowska J, Stella-Holowiecka B, Mital A, Obara A, Szmigielska-Kaplon A, Sikorska A, Subocz E, Jedrzejczak WW, Dwilewicz-Trojaczek J
Institution:Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Poland. Warsaw, Poland. Warsaw, Poland. Warsaw, Poland. University, Katowice, Poland. Gdansk, Poland. Poland. Warszawa, Poland. Warsaw, Poland. Warsaw, Poland.
Journal:Adv Clin Exp Med. 2016 Jul-Aug;25(4):633-41. doi: 10.17219/acem/62397.

7:Efficacy and adverse events of azacitidine in the treatment of hemodialysis patients with high-risk myelodysplastic syndrome.
Authors:Yoshihiro T, Muta T, Aoki K, Shimamoto S, Tamura Y, Ogawa R
Institution:Department of General Medicine, Japan Community Health Care Organization (JCHO) Kyushu Hospital.
Journal:Rinsho Ketsueki. 2016 Aug;57(8):1004-10. doi: 10.11406/rinketsu.57.1004.

8:Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Authors:Mittelman M, Filanovsky K, Ofran Y, Rosenbaum H, Raanani P, Braester A, Goldschmidt N, Kirgner I, Herishanu Y, Perri C, Ellis M, Oster HS
Institution:Department of Medicine A, Tel Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv, 64239, Israel. moshemt@tlvmc.gov.il. moshemt@tlvmc.gov.il. Aviv, 64239, Israel. Aviv, 64239, Israel. Aviv, 64239, Israel. Aviv, 64239, Israel.
Journal:Ann Hematol. 2016 Oct;95(11):1811-8. doi: 10.1007/s00277-016-2776-x. Epub 2016 Aug 22.

9:Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Authors:Lee YJ, Park SW, Lee IH, Ahn JS, Kim HJ, Chung JS, Shin HJ, Lee WS, Lee SM, Joo YD, Kim H, Lee HS, Kim YS, Cho YY, Moon JH, Sohn SK
Institution:Department of Hematology/Oncology, Kyungpook National University Hospital, 130 Dongduk-Ro, Jung-Gu, Daegu, 41944, South Korea. Dongduk-Ro, Jung-Gu, Daegu, 41944, South Korea. Dongduk-Ro, Jung-Gu, Daegu, 41944, South Korea. Gwangju, South Korea. Gwangju, South Korea. South Korea. South Korea. South Korea. South Korea. Busan, South Korea. Korea. Korea. Daegu, South Korea. Dongduk-Ro, Jung-Gu, Daegu, 41944, South Korea. jhmoon74@knu.ac.kr. Dongduk-Ro, Jung-Gu, Daegu, 41944, South Korea. sksohn@knu.ac.kr.
Journal:Ann Hematol. 2016 Oct;95(11):1795-804. doi: 10.1007/s00277-016-2759-y. Epub 2016 Aug 17.

10:Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Authors:Mo XD, Qin YZ, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, Chen YH, Han W, Wang FR, Wang JZ, Liu KY, Huang XJ
Institution:Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. huangxiaojun@bjmu.edu.cn. huangxiaojun@bjmu.edu.cn. China. huangxiaojun@bjmu.edu.cn.
Journal:Ann Hematol. 2016 Aug;95(8):1233-40. doi: 10.1007/s00277-016-2706-y. Epub 2016 Jun 14.

11:Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.
Authors:Zahid MF, Patnaik MM, Gangat N, Hashmi SK, Rizzieri DA
Institution:Medical graduate, Aga Khan University, Karachi, Pakistan. faizanzahid91@hotmail.com. Rochester, MN, USA. Rochester, MN, USA. Center, Durham, NC, USA.
Journal:Eur J Haematol. 2016 Oct;97(4):313-20. doi: 10.1111/ejh.12771. Epub 2016 May 31.

12:Laboratory and clinical risk assessment to treat myelodysplatic syndromes.
Authors:Gidaro A, Deliliers GL, Gallipoli P, Arquati M, Wu MA, Castelli R
Journal:Clin Chem Lab Med. 2016 Sep 1;54(9):1411-26. doi: 10.1515/cclm-2015-0789.

13:Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
Authors:Fujimaki K, Miyashita K, Kawasaki R, Tomita N
Institution:Department of Hematology, Fujisawa City Hospital, Fujisawa, Japan. Graduate School of Medicine, Yokohama, Japan.
Journal:Eur J Haematol. 2016 Sep;97(3):228-31. doi: 10.1111/ejh.12709. Epub 2016 Jan 3.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: January 22, 2017
152 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS52405207

Coupon Expires: May 25, 2017



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.